首页> 外文期刊>Science China Life Sciences >Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro
【24h】

Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro

机译:Hsa-miR-1246,hsa-miR-320a和hsa-miR-196b-5p抑制剂可降低埃​​博拉病毒糖蛋白的细胞毒性

获取原文
           

摘要

Ebola virus (EBOV) causes a highly lethal hemorrhagic fever syndrome in humans and has been associated with mortality rates of up to 91% in Zaire, the most lethal strain. Though the viral envelope glycoprotein (GP) mediates widespread inflammation and cellular damage, these changes have mainly focused on alterations at the protein level, the role of microRNAs (miRNAs) in the molecular pathogenesis underlying this lethal disease is not fully understood. Here, we report that the mi-RNAs hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p were induced in human umbilical vein endothelial cells (HUVECs) following expression of EBOV GP. Among the proteins encoded by predicted targets of these miRNAs, the adhesion-related molecules tissue factor pathway inhibitor (TFPI), dystroglycan1 (DAG1) and the caspase 8 and FADD-like apoptosis regulator (CFLAR) were significantly downregulated in EBOV GP-expressing HUVECs. Moreover, inhibition of hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p, or overexpression of TFPI, DAG1 and CFLAR rescued the cell viability that was induced by EBOV GP. Our results provide a novel molecular basis for EBOV pathogenesis and may contribute to the development of strategies to protect against future EBOV pandemics.
机译:埃博拉病毒(EBOV)在人类中引起高度致死性出血热综合征,在最致命的菌株扎伊尔中,其死亡率高达91%。尽管病毒包膜糖蛋白(GP)介导了广泛的炎症和细胞损伤,但这些变化主要集中在蛋白质水平的变化上,尚未完全了解微RNA(miRNA)在这种致命疾病的分子发病机理中的作用。在这里,我们报道在EBOV GP表达后,在人脐静脉内皮细胞(HUVEC)中诱导了mi-RNA hsa-miR-1246,hsa-miR-320a和hsa-miR-196b-5p。在这些miRNA的预测靶标编码的蛋白质中,粘附相关分子组织因子途径抑制剂(TFPI),dystroglycan1(DAG1)和caspase 8和FADD样凋亡调节剂(CFLAR)在表达EBOV GP的HUVEC中显着下调。 。此外,抑制hsa-miR-1246,hsa-miR-320a和hsa-miR-196b-5p或TFPI,DAG1和CFLAR的过表达可以挽救EBOV GP诱导的细胞活力。我们的研究结果为EBOV发病机理提供了新的分子基础,并且可能有助于开发针对未来EBOV大流行的防御策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号